2. >>Business
  3. >>Deals

With Dicerna's NASH Asset, Boehringer Found What It Was Looking For

 
• By Joseph Haas

In eyeing NASH, the firms both zeroed in on the same target, considered inaccessible to traditional modalities. The deal gives BI an RNAi approach, joining its Phase II anti-inflammatory candidate for NASH.

Two businessmen shaking hands during a meeting in the office, success, dealing, greeting & business partner concepts - soft light.

Dicerna Pharmaceuticals Inc. and Boehringer Ingelheim GMBH have linked up to evaluate an RNA-interference approach to an undisclosed, difficult-to-drug target for non-alcoholic steatohepatitis (NASH) – one each company had been working on separately.

The transaction, which may kick-start Dicerna's new partnering strategy as it carries out a shift in R&D direction, would give the Cambridge, Mass.-based biotech up to $201m under the pact unveiled Nov. 2. The sum includes an upfront payment and the potential for a licensing fee, R&D cost reimbursement, and development and commercialization milestone fees

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

 
• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.

UK-India FTA Could Offer ‘Significant Benefits’ For Generics, Biosimilars

 
• By Dave Wallace

A free trade agreement between the UK and India could offer “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments.

Will Other Major MASH Deals Follow GSK/Boston Pharma?

 
• By Joseph Haas

GSK’s $1.2bn payout for Boston Pharma’s efimosfermin is the first billion-dollar-plus MASH deal in nearly nine years, but several other advanced MASH programs could be positioned for takeout.